Results 1 to 10 of about 25,259 (185)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon

Sultan Qaboos University Medical Journal, 2002
Objectives: To assess whether a combination of pegylated interferon (interferon conjugated with polyethylene glycol) and ribavirin can improve the response rate in patients with chronic hepatitis C who either did not respond to (Non-responders), or had ...
Hisham O. Akbar, Mahmoud S. Al Ahwal
doaj   +3 more sources

Pegylated interferon: the who, why, and how. [PDF]

Hematology Am Soc Hematol Educ Program
Abstract Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms.
Kiladjian JJ.
europepmc   +3 more sources

Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A [PDF]

Pathology and Oncology Research
IntroductionHairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. Interferon-alpha (IFN-alpha) was the first successfully used drug in HCL; its favourable effect has been known since the early 1980s.
Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter   +6 more
doaj   +2 more sources

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations [PDF]

Therapeutic Advances in Hematology
Pegylated interferons alfa are increasingly used in patients with myeloproliferative neoplasms (MPN) due to their potential disease-modifying effect. Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic ...
Axel Rüfer, Christoph Brand, Andrea de Gottardi, Stefan Fischli, Ralph Melzer, Urs Odermatt, Walter A. Wuillemin, Sacha S. Zeerleder   +7 more
doaj   +2 more sources

Clinical Characteristics and Factors Associated with Hair Loss Severity in Chronic Hepatitis B Patients Receiving Pegylated Interferon-Alpha: A Retrospective Cohort Study. [PDF]

Clin Cosmet Investig Dermatol
Wang X, Yan Z, Liu C, Gao Y.
europepmc   +3 more sources

Season-adjusted longitudinal changes in serum 25-hydroxyvitamin D during pegylated interferon add-on to ongoing tenofovir alafenamide therapy in chronic hepatitis B: a real-world cohort study [PDF]

Front Med (Lausanne)
Han N, Liu H, Zhu X.
europepmc   +3 more sources

Effect of pegylated interferon α-2b on low-density lipoprotein in patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Xu B, Fan A, Qian B, Liang J, Li T, Yin W, Xiang H, Ye Q.   +7 more
europepmc   +3 more sources

Impact of nonalcoholic fatty liver disease on the response to pegylated interferon-α therapy in patients with chronic hepatitis B. [PDF]

Microbiol Spectr
Liang H, Xie Y, Dai Y, Yang X, Zheng X, Yang J, Liu Y, Wu C, Chen S, Zhang M, Zhuang H, Lin L, Chen S.   +12 more
europepmc   +3 more sources

HBsAg seroreversion after pegylated interferon alpha induced HBsAg seroclearance in patients with chronic hepatitis B: a real-world cohort study. [PDF]

BMC Infect Dis
Zhang W, Chen J, Sun W, Xie N, Tian F, Zhang W, Wang Y, Ruan Q, Song J.   +8 more
europepmc   +2 more sources

Efficacy and Metabolic Effects of Pegylated Interferon α-2b versus Nucleos(T)ide Analogues in Patients with Chronic Hepatitis B and Concomitant Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Study. [PDF]

Hepat Med
Liu Y, Wang H, Zheng X, He C, Xie Y, Dai Y, Chen H, Liu Z, Chen S, Liang H.   +9 more
europepmc   +3 more sources